In this issue of Blood, Hengeveld et al describe an openly available, highly sensitive next-generation sequencing approach developed to track minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL).(1) This tool improved patients' outcome prediction in comparison with the traditionally available MRD tools.
Looking for a needle in the haystack of CLL
Ferrero, Simone
First
;Genuardi, Elisa
2023-01-01
Abstract
In this issue of Blood, Hengeveld et al describe an openly available, highly sensitive next-generation sequencing approach developed to track minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL).(1) This tool improved patients' outcome prediction in comparison with the traditionally available MRD tools.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
